Download our free ebook: your guide to CRPS filled with incredible knowledge on the condition

CRPS Treatment: pain in ankle for 1 year and a half

General details and patient's info

Age:41 years old at the time of treatment.
Home Country:United States of America.
Illness duration:19 months prior to the Neridronate Treatment.
Cause:Left hip arthroscopy.
Symptoms:Constant severe burning pain. Weakness in left leg. Cannot tolerate touch nor moving too much. Cannot climb stairs.
Clinical evaluation:CRPS diagnosis lower left limb. Lumbar radicular pain, neuropathic pain.
Time of treatment:March 2017.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient was in a lot of Facebook CRPS support groups, once someone posted about the Neridronate treatment in Italy and how it had changed her life, so she started looking into in online. She found the main article on the study made by Doctor Adami, and at the bottom she found MTI’s number for foreign patients and decided to call.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website:
4 Pantoprazole infusions; Paracetamol;

Daily Report

DAY 1: Arrival at the Verona train station, greeted by her Patient Manager, followed by check-in at her Hotel in Verona. Briefing focused on next days.

DAY 2: Rest Day, in contact with her Patient Manager

DAY 3: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor and 1st Neridronate infusion.

DAY 4: Morning pick-up by her Patient Manager, 2nd Neridronate infusion.

DAY 5: Morning pick-up by her Patient Manager and 3rd Neridronate infusion.

DAY 6: Morning pick-up by her Patient Manager, 2nd visit with the Rheumatologist Professor, last Neridronate infusion.

DAY 7: Morning meeting with her Patient Manager, rest day.

DAY 8: Morning pick-up by her Patient Manager and drop-off at Verona train station.

Follow up

APRIL 2017 (1 month after Neridronate treatment): the patient feels better, she could walk just a few days after the last infusion.

DECEMBER 2018 (21 months after Neridronate treatment): the patient is doing well, pain decreased, and she is back to her normal life.

JUNE 2019 (27 months after Neridronate treatment): the patient is in remission.

APRIL 2022 (5 years after Neridronate treatment): the patient is in a lasting remission.


The patient is in a lasting remission.
This patient and her husband are now spreading their experience and try to help other people to understand the efficacy of this option.

This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.